Neurotech Secures US Patent Allowances for NTI164, Extending Protection to 2042

USPTO Advances Key Patents for NTI164

Clinical-stage biopharmaceutical company Neurotech International (ASX:NTI) has taken a significant step in securing its intellectual property around NTI164, its cannabinoid-based therapy targeting paediatric neurological disorders. The United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for two patent applications, signalling that formal patent grants are expected within months.

The two patent applications, numbered 18/698,605 and 19/335,945, cover critical aspects of NTI164: one protects methods of reducing neuroinflammation, while the other focuses specifically on treating autism spectrum disorder (ASD). These patents, once granted, will extend protection for NTI164 through to 2042, reinforcing Neurotech’s competitive moat in a crowded and evolving biopharma landscape.

Strengthening IP Amid Phase 3 Clinical Progress

NTI164 is currently in Phase 3 clinical development for ASD in children, a stage that demands robust intellectual property to underpin future commercialisation and licensing opportunities. The Notices of Allowance confirm the USPTO’s satisfaction with the patentability of these inventions, though enforcement rights will only begin once the patents are formally granted and all administrative processes are complete.

This development complements Neurotech’s recent clinical milestones, including the activation of its first Phase 3 trial site and positive safety data reported earlier this year. The company’s CEO, Anthony Filippis, emphasised that these allowances are part of a broader strategy to protect and build value around NTI164 as it advances through pivotal trials.

NTI164’s Unique Formulation and Therapeutic Promise

NTI164 is a proprietary, GMP-grade, multi-constituent formulation rich in CBDA and select minor cannabinoids. Preclinical and early clinical studies have shown its potential to modulate neuroinflammatory pathways and immune dysregulation, mechanisms implicated in neurodevelopmental disorders such as ASD. Earlier trials have demonstrated statistically significant benefits with a favourable safety profile, supporting the rationale for the ongoing Phase 3 study.

As the company prepares for the expected patent grants, the intellectual property coverage will solidify NTI164’s position in a niche yet critical therapeutic area, potentially opening doors for partnerships or regulatory submissions in key markets including the US and Australia.